News
A Thai doctor issued a warning after a patient injected sperm into his body in an attempt to treat back pain, leading to the ...
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme ...
Company News Published 06/20/2025, 01:22 PM 0 Argenx receives EU approval for VYVGART subcutaneous injection HALO -0.36% ...
SAN DIEGO - Halozyme Therapeutics, Inc. (NASDAQ: HALO), a $6.5 billion biotech company with exceptional financial health according to InvestingPro metrics, announced today that argenx has received ...
VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDPApproval based on ADHERE clinical trial ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
News release. Merck. March 27, 2025. Accessed May 25, 2025. https://bit.ly/43dSAQz 2. Steinzor P. FDA approves first subcutaneous nivolumab injection in most solid tumors. AJMC. January 2, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results